The transaction includes $150 million in cash at closing and $100 million in cash payable in 2021.
“This deal aligns with our active portfolio management strategy and the ongoing transformation of our business that will position Zimmer Biomet for long-term growth,” Bryan Hanson, the company’s president and CEO, said in a Dec. 1 news release.
A&E Medical’s portfolio of sternal closure devices, including sutures, cables and fixation systems, are now part of the Zimmer Biomet umbrella.
Revenue from the portfolio is expected to be recognized in Zimmer Biomet’s dental, spine and craniomaxillofacial and thoracic business unit.
The transaction is not expected to have a significant effect on 2020 net earnings.
More articles on devices:
Dr. Daniel Lieberman: How hospitals will react to outpatient migration & what’s next for spine at ASCs
Illinois Bone & Joint Institute CEO on M&As in 2020 and future strategy
Nick Saban lauds orthopedic surgeon named as SEC Team Physician of the Year
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.